3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Nasopharyngeal Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Solid Tumors
1
Interventions
atezolizumab
3
Trastuzumab
2
tocilizumab
1
spartalizumab
1
pralsetinib
1
pertuzumab
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
olaparib
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
cemiplimab
1
anlotinib
1
alectinib
1
adagrasib
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Filgrastim
1
Docetaxel
1
Cyclophosphamide
1
Cetuximab
1
Capecitabine
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
Immune Checkpoint Inhibitors
×
30 days
×
Clear all
No trials found.